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ABSTRACT 23 
RNA structural elements occur in numerous single stranded (+)-sense RNA viruses. The 24 
stem-loop 2 motif (s2m) is one such element with an unusually high degree of sequence 25 
conservation, being found in the 3ʹ UTR in the genomes of many astroviruses, some 26 
picornaviruses and noroviruses, and a variety of coronaviruses, including SARS-CoV and 27 
SARS-CoV-2. The evolutionary conservation and its occurrence in all viral subgenomic 28 
transcripts implicates a key role of s2m in the viral infection cycle. Our findings indicate that 29 
the element, while stably folded, can nonetheless be invaded and remodelled spontaneously 30 
by antisense oligonucleotides (ASOs) that initiate pairing in exposed loops and trigger 31 
efficient sequence-specific RNA cleavage in reporter assays. ASOs also act to inhibit 32 
replication in an astrovirus replicon model system in a sequence-specific, dose-dependent 33 
manner and inhibit SARS-CoV-2 replication in cell culture. Our results thus permit us to 34 
suggest that the s2m element is readily targeted by ASOs, which show promise as anti-viral 35 
agents. 36 
IMPORTANCE 37 
The highly conserved stem-loop 2 motif (s2m) is found in the genomes of many RNA viruses 38 
including SARS-CoV-2. Our findings indicate that the s2m element can be targeted by 39 
antisense oligonucleotides. The anti-viral potential of this conserved element represents a 40 
promising start for further research into targeting conserved elements in RNA viruses. 41 
KEY WORDS 42 
plus-strand RNA virus, coronavirus, astrovirus, s2m, gapmer, LNA, therapeutic 43 
oligonucleotides, SARS-CoV-2  44 
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INTRODUCTION 45 
SARS-CoV-2 is a highly infectious virus and the causative agent of the ongoing COVID-46 
19 pandemic. Given the continued rise in cases worldwide, the significant mortality rate and 47 
the challenges in predicting the severity of illness in infected individuals (1), there is a 48 
pressing need for efficacious antiviral therapies (2, 3) 49 
(https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Moreover, the potential 50 
for further outbreaks of infections by emerging pathogenic coronaviruses (4, 5) places 51 
importance on improving fundamental understanding of coronavirus biology, as well as 52 
exploring novel therapeutics that could be rapidly repurposed in response to the next zoonotic 53 
jump. 54 
Like other positive-sense (+) single-stranded (ss) RNA viruses, replication of SARS-CoV-55 
2 is orchestrated by virus-encoded enzymes inside infected host cells. The 30 kb long SARS-56 
CoV-2 genomic RNA and the subgenomic mRNA transcripts all contain a common 5ʹ-leader 57 
sequence and a common 3ʹ UTR, which harbour several conserved structural elements, 58 
including the stem-loop 2 motif (s2m) (Fig. 1A and B) (6, 7). The s2m, originally identified 59 
in astroviruses (8), is a highly conserved RNA sequence element, present within the 3ʹ UTR 60 
in the genomes of many astroviruses, some picornaviruses and noroviruses, and a variety of 61 
coronaviruses, including members of the subgenus Sarbecovirus, which includes SARS-CoV 62 
and SARS-CoV-2 viruses (9, 10). The SARS-CoV and SARS-CoV-2 s2m sequences are 63 
nearly identical, with only 2 point nucleotide differences (Fig. 1A), in contrast to the overall 64 
20 % genome-wide sequence divergence (7). The s2m sequence is also highly conserved in 65 
the clinical isolates from patients that have tested positive for SARS-CoV-2 during the 66 
current pandemic, although with a few isolated exceptions (GSAID database 67 
https://www.gisaid.org; UCSC genome browser) (11, 12). The high degree of s2m sequence 68 
conservation is likely to be a direct consequence of a requirement to sustain an elaborate 69 
three-dimensional structure. Indeed, an earlier study of the SARS-CoV s2m element revealed 70 
a stable stem loop with a few exposed bases (Fig. 1B) in a 2.7 Å resolution crystal structure 71 
(13). Several more recent studies probed RNA accessibility and mapped RNA-RNA 72 
interactions of the (+) sense SARS-CoV-2 viral RNAs inside the host cell, confirming that 73 
the s2m stem-loop structure folds in vivo as well (14, 15). 74 
Because of the apparent high degree of selective pressure to maintain this specific 75 
sequence and its structure, the s2m is a promising target for potential antiviral agents, with 76 
reduced likelihood of evolving mutations that would lead to resistance. Since the s2m 77 
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element is present in all (+)-sense transcripts (both genomic and subgenomic) produced by a 78 
given virus, any agents targeting the s2m would also have the advantage of acting against the 79 
majority of viral RNAs present within a cell. In order to test the accessibility of the s2m 80 
element to potential nucleic acid-based therapeutics, we designed a panel of antisense 81 
oligonucleotides (ASOs). These oligonucleotides have proven therapeutic potential against 82 
viruses and have been undergoing active development for more than a decade (16). Third-83 
generation ASOs include locked nucleic acids (LNAs), in which a bicyclic linkage at the 84 
furanose constrains the conformational freedom of the nucleotide (17). LNAs provide high 85 
affinity base-pairing to complementary RNA and DNA targets, as well as resistance to 86 
nuclease attack (18). A version of LNA ASOs known as ‘gapmers’ consist of LNA bases 87 
flanking a central DNA sequence (19). In this design, LNA bases confer resistance to 88 
nucleases and provide high-affinity base-pairing to the RNA target, while the central DNA 89 
region, once base-paired to RNA, recruits ribonuclease H (RNase H), which acts to cleave the 90 
RNA in the RNA-DNA duplex. In this process, the DNA is not digested and thus the gapmer 91 
remains intact and free to bind further RNA molecules, directing their cleavage. Gapmers 92 
have already been successfully used in clinical trials to catalyse the degradation of target 93 
transcripts (20). 94 
In this report, we describe the design and testing of several LNA ASOs (gapmers) against 95 
the highly conserved structured s2m element from the 3ʹ UTR of SARS-CoV-2. By 96 
performing chemical probing of the RNA, we found that ASOs successfully remodel the s2m 97 
structure, despite its high degree of structural compactness. Furthermore, gapmers were 98 
capable of inducing sequence-specific RNA cleavage in vitro and had an inhibitory effect in 99 
multiple independent cell-based platforms, including a human cell reporter system, an 100 
astrovirus replicon assay, and SARS-CoV-2 replication in infected cells. Our results support 101 
targeting of the s2m element and other conserved structures with predicted exposed loops in 102 
viral genomes by ASOs. In addition, the particular gapmer designs described here may offer 103 
suitable lead compounds for further development as antiviral therapeutics to treat COVID-19 104 
and other diseases caused by RNA viruses possessing the s2m element in their genomes. 105 
RESULTS 106 
Model for the s2m element in the context of the SARS-CoV-2 3ʹ UTR. Given the high 107 
sequence similarity between the s2m elements in the SARS-CoV-2 and SARS-CoV genomes 108 
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(Fig. 1A), the corresponding structures are expected to show high similarity as well, although 109 
recent NMR data suggests some differences in their secondary structures (21). 110 
The crystal structure of the SARS-CoV s2m reveals a stem loop with a small pocket that 111 
can accommodate cations (Fig. 1B) (13) and suggests a similar fold for the SARS-CoV-2 112 
s2m. To test this experimentally, we probed the structure of the SARS-CoV-2 s2m element 113 
within the genomic 3ʹ UTR using SHAPE (Selective 2′-Hydroxyl Acylation analyzed by 114 
Primer Extension) (22). The SHAPE reactivity profile agrees with the crystal structure of the 115 
SARS-CoV s2m element (Fig. 1C-D). For instance, high SHAPE reactivities were found at 116 
the loop region (G71-A75), indicating strong possibility of a single-stranded nature, while 117 
low SHAPE reactivities were found for nucleotides predicted to be base-paired, such as 118 
nucleotides 54-58, and nucleotides 90-94 (Fig. 1D). We have compared our results from gel-119 
based SHAPE analysis (Fig. 1C) with the previous analyses by Manfredonia et al. (23), 120 
performed on the full-length virus genome using SHAPE-MaP profiling (Fig. 1E, Table 1). 121 
We found an especially high correlation (PCC = 0.77) between our data and SHAPE-MaP 122 
reactivities (Fig. 1E) for the s2m region, indicating that the s2m is an intrinsic structural 123 
module. Stable structural unit formation by s2m, maintained within an extended surrounding 124 
sequence, has also been observed in a recent NMR and DMS chemical probing study (21). 125 
To further investigate potential structures formed by the viral 3ʹ UTR as a whole, we used 126 
cryo-electron microscopy. Imaging this RNA fragment mainly yielded elongated shapes 127 
resembling thick rope, up to 500 Å in length (Fig. 1F). A subset of the ropey particles were 128 
less extended, measuring around 300 Å, which is about half the length expected for an 129 
elongated polymer, implying that the RNA there is semi-compact. These particles were 130 
subjected to computational 2D/3D averaging in an attempt to reveal underlying shared 131 
structural features (Fig. 1G-H). However, none could be clearly identified, suggesting that the 132 
3ʹ UTR RNA does not fold into a well-defined structure, at least in vitro. 133 
Our cryo-electron microscopy observations give support to earlier in vivo studies, where 134 
cells infected with SARS-CoV-2 virus were probed by cryo-electron tomography (24). Both 135 
the tomography study and our single-particle imaging reveal small, high-contrast features at 136 
the periphery of the RNA particles, which might represent views down the long axis of some 137 
duplex RNA regions (Fig. 1F, red arrows). 138 
Overall, based on the prediction from the SARS-CoV s2m RNA crystal structure and our 139 
SHAPE probing results, we conclude that the s2m element in the 3ʹ UTR of SARS-CoV-2 140 
RNA folds into a stem-loop structure, which may be highly conserved among coronaviruses. 141 
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This is in contrast to the entire 3ʹ UTR as a whole, for which we do not observe any well-142 
defined global structure. 143 
Binding and activity of LNA ASO gapmers against the s2m element in vitro. Although 144 
the highly conserved sequence of the s2m element makes it an attractive target for therapies 145 
based on ASOs, the structured nature of the target may potentially interfere with ASO-target 146 
base-pairing. To facilitate gapmer-induced disruption of the native s2m structure, we 147 
designed gapmers so that the high-affinity LNA bases would pair with the RNA bases 148 
predicted to be exposed in the s2m element (Fig. 2 and Table 2). This pairing should facilitate 149 
initial gapmer-target interaction, hypothetically leading to unfolding of the s2m element as 150 
the rest of the gapmer base-pairs with the complementary target nucleotides. 151 
We designed a panel of gapmers and tested their ability to direct RNase H cleavage in 152 
vitro, using s2m RNA as the substrate for the purified enzyme (Fig. 2A and D). Different 153 
gapmer-target affinities were trialled: gapmers 1-3 were designed to have higher affinity for 154 
target RNA than gapmers 4-6, as indicated by respective predicted melting temperatures 155 
(schematic top panel, Fig. 2 and Table 2). The presence of the sequence-specific gapmers 1-6 156 
in the digestion reactions led to clear degradation of the target s2m RNA, regardless of their 157 
predicted melting temperature bracket, whereas a non-sequence-specific control gapmer with 158 
scrambled sequence failed to have an effect (“scr”, Fig. 2D). The degradation was very 159 
efficient even for a 2:1 s2m:gapmer molar ratio, indicating that gapmers can be recycled and 160 
can direct multiple turnover of substrates by RNase H. Gapmers 1-6 also drove cleavage of 161 
the whole 3ʹ UTR (Fig. 2B and E) and of the “extended 3ʹ UTR” construct that additionally 162 
includes ORF10 and the region immediately upstream of it (Fig. 2F, Table 3), indicating that 163 
the target s2m sequence is successfully recognised and is accessible for gapmer base-pairing 164 
in the context of the longer 3ʹ UTR. The observation that both the higher-affinity gapmers 1-3 165 
(Fig. 2A and B) and the lower-affinity gapmers 4-6 (Fig. 2 D, E and F) were able to direct 166 
RNase H cleavage of the s2m element indicates that a range of gapmer-target affinities are 167 
compatible with successful target degradation of the highly structured s2m sequence. This 168 
flexibility in gapmer design is particularly encouraging for potential development of 169 
therapeutics, as lower affinity gapmers may be expected to have fewer off-target interactions 170 
in cells than the higher-affinity variants. 171 
Additionally, we designed and tested gapmers targeting a single-stranded conserved 172 
region in SARS-CoV-2, at position 1359-1374 relative to the NC_045512.2 virus reference 173 
genome (“ss3”) (6) and tested alternative gapmer backbone chemistries with these. Gapmers 174 
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designated “all” and “some” have the same sequence and base composition, but different 175 
polymer backbones (Table 2). The entire backbone of gapmer “all” contains 176 
phosphorothioate modifications, as is also the case in gapmers 1-6; it is a well-established 177 
modification conferring some nuclease resistance to oligonucleotides (25, 26). The backbone 178 
in gapmer “some”, however, is mixed; DNA bases are linked by a phosphodiester backbone, 179 
whereas LNA bases are linked by a phosphorothioate backbone. 180 
In vitro digestion experiments (Fig. 2C) indicate that both chemistries are compatible with 181 
RNase H recruitment and the degradation of the RNA target, and also suggest general 182 
applicability of gapmer-directed cleavage of virus RNA sequences. Gapmer “some” appears 183 
to have higher binding affinity for the “ss3” target, judging from the presence of an extra 184 
band at the top of the gel in Fig. 2C, which likely corresponds to a gapmer-target dimer. This 185 
is consistent with expectation, as phosphorothioate modifications are known to reduce target 186 
affinity (27), so gapmer “all” would be expected to show weaker binding than gapmer 187 
“some”. On the other hand, gapmer “all” generates a higher amount of cleaved product 188 
(Fig. 2C), which supports our choice of a phosphorothioate backbone throughout gapmers 1-189 
6. 190 
Despite being structured, the s2m is successfully remodelled by LNA gapmers. To 191 
confirm that gapmers affect the s2m structure, we performed SHAPE probing of SARS-CoV-192 
2 3′ UTR in the presence of gapmers 1, 2 and 3 targeting s2m and gapmer “all” as a non-193 
specific control. Since SHAPE probing detects the accessibility of nucleotides (22), it is 194 
capable of revealing both intra- and inter-molecular RNA base-pairing interactions. 195 
In the presence of gapmer 1, SHAPE reactivity profiles strongly decreased in the gapmer-196 
targeted region G60-C69 (Fig. 3A-B), indicating successful gapmer-target base-pairing. Due 197 
to the interaction between the gapmer and its target site, the other arm of the s2m (U79-A94) 198 
loses base-pairing interactions and becomes more single-stranded, as evidenced by a strong 199 
increase in SHAPE reactivity in this region (Fig. 3A-B). We also found slightly decreased 200 
SHAPE reactivities in the region A75-A78 and increased SHAPE reactivities in the region 201 
G70-A75. The latter might be due to a dynamic interaction between the 3ʹ end of the gapmer 202 
and the target site or due to conformational remodelling leading to a higher accessibility of 203 
the SHAPE reagent to the 2ʹ-OH of these nucleotides. Similar changes in SHAPE reactivities 204 
were also observed in the presence of gapmer 2 (Fig. 3C-D), which targets s2m with a 1 nt 205 
shift compared to the target site of gapmer 1 (G60-C76 and C59-A75, respectively). 206 
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In the presence of gapmer 3, which targets the single-stranded loop region within s2m, the 207 
SHAPE reactivity profile showed a strong decrease in the region G60-A75 (Fig. 3E-F), 208 
indicating successful base-pairing interactions with the gapmer. We also found that this inter-209 
molecular interaction between gapmer 3 and the loop region led to increased SHAPE 210 
reactivities downstream of the loop region. Thus, the inter-molecular interactions between 211 
gapmers and target regions could also remodel the folding status of flanking regions. 212 
Notably, the observed changes in SHAPE reactivity were dependent on the concentration 213 
of gapmers and were not detected in the presence of a control gapmer (gapmer “all”) which is 214 
not able to target the s2m element (Fig. 3G-H). Taken together, our results validate the design 215 
of gapmers in targeting the s2m element and highlight the effect of gapmers in remodelling 216 
the s2m structure to gain access to a highly structured RNA. 217 
s2m induces gapmer-directed reduction of reporter gene expression in human cells. 218 
To investigate if gapmers against the s2m element could drive target RNA degradation in 219 
human cells, we set up a tissue culture-based reporter system. We generated lung-derived 220 
A549 and HeLa cell reporter lines carrying stably integrated GFP genes that encode either the 221 
wild type s2m element or a scrambled control sequence in their 3ʹ UTR (Fig. 4A-C). 222 
Transfection with gapmers against s2m reduced GFP fluorescence levels in the two s2m-223 
containing cell lines for both the higher-affinity gapmers 1-3 and the lower-affinity gapmers 224 
5-6 (Fig. 4D and F). Gapmer 4, the shortest of the tested gapmers and containing only six 225 
DNA nucleotides (Table 2), had no effect (Fig. 4D and F); this may reflect difficulties in 226 
recruiting human RNase H in vivo to this length of RNA-DNA duplex (28). Non-specific 227 
control gapmers did not affect GFP fluorescence levels, nor did treatment with s2m-specific 228 
gapmers of control cell lines in which the sequence of the s2m element was scrambled 229 
(Fig. 4E and G). These results indicate that the gapmer-mediated reduction in target gene 230 
expression relies on sequence-specific gapmer-target interaction. Overall, the results indicate 231 
that gapmers against the s2m element have the potential to decrease gene expression from 232 
mRNAs containing s2m in their 3ʹ UTR sequences, which is the case for SARS-CoV-2 233 
mRNAs. 234 
Our experimental method was also used to test the hypothesis that the s2m is a post-235 
transcriptional response element. We used the GFP reporter cell lines to compare 236 
fluorescence levels between the GFP-s2m and GFP-scrambled cells. No difference was 237 
observed, indicating that the s2m element itself does not affect fluorescent protein production 238 
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(Fig. 4C), which suggests that it does not act as an independent element in cis in translation 239 
or stability of viral mRNAs. 240 
LNA gapmers against s2m inhibit replication in an astrovirus replicon model system 241 
in human cells. To investigate the effects of s2m-targeting LNA gapmers on viral 242 
replication, initially we employed an astrovirus replicon system, where the measured 243 
luciferase signal represents the translation of a reporter protein from subgenomic RNAs. 244 
Many (+) ssRNA viruses share a similar repertoire of genetic elements required for the 245 
replication of viral RNA, and this is true in the case of coronaviruses and astroviruses. 246 
Despite a large disparity in genome size, coronaviruses and astroviruses possess a similar 247 
modular organization, with a largely similar ordering of non-structural and structural genes, a 248 
frameshift signal to access the open reading frame encoding the RNA-dependent RNA 249 
polymerase (RdRp), and production of 3ʹ-coterminal subgenomic mRNAs for structural and 250 
accessory protein expression. Like coronaviruses, many astroviruses – including human 251 
astrovirus 1 (HAstV1) – contain an s2m element in the 3ʹ UTR of their genomes (Fig. 5A). 252 
We have recently developed a robust HAstV1-based replicon system (Fig. 5A, lower panel), 253 
which permits the evaluation of RNA replication in multiple cell types (29). The small 254 
astrovirus genome size (~7 kb) compared to the much larger coronaviruses (~30 kb), allows 255 
for rapid manipulation of sequences for anti-viral testing in a less restrictive environment 256 
than that required to manipulate SARS-CoV-2. 257 
Building on promising results in the cell-based reporter system, we used the astrovirus 258 
system to test gapmer efficacy in the context of virus-like replication, where replicative 259 
intermediates are generally physically occluded within host membrane derived vesicles, as is 260 
also the case in bona fide virus infection. We generated chimeric astrovirus replicons bearing 261 
the s2m elements from SARS-CoV or SARS-CoV-2 (Fig. 5B). Chimeric replicons 262 
recapitulated the replication properties of the wild-type astrovirus replicon (Fig. 5C), 263 
indicating that this system is suitable for testing gapmers against multiple s2m sequences. To 264 
rule out any potential cell-specific effects, all gapmers were tested in two human cell lines – 265 
Huh7.5.1 (29) and HEK293T (optimised for this study). The replication of replicons bearing 266 
SARS-CoV-2 s2m sequences was efficiently inhibited by gapmers 1, 2, and 5, causing 267 
inhibition in the sub-nanomolar range, with a less pronounced effect found for gapmers 3, 4, 268 
and 6. The inhibition of non-specific control gapmers (“all” and “scr”) was significantly 269 
below their composition-matched counterparts, gapmers 1-3 and 4-6, respectively (Fig. 5D, 270 
Table 4). The same gapmers were also tested against the SARS-CoV s2m in this system and 271 
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found to be active, though with a lower potency (Fig. 5E, Table 5). This could potentially be 272 
attributed to differences arising from C-G versus C-U juxtaposition within the respective s2m 273 
elements (Fig. 5B) (30), potentially affecting the s2m gapmer binding properties. Replication 274 
in the presence of sufficient concentrations of gapmers 1, 2 or 5 dropped to the baseline level 275 
of the pO2RL-GNN mutant (Tables 4 and 5), which is completely deficient in replication due 276 
to a mutated RdRp active site (Fig. 5C). 277 
To assess the cytotoxicity and potential off-target effects of the tested gapmers, we (i) 278 
performed a lactate dehydrogenase release-based cytotoxicity assay, and (ii) evaluated the 279 
efficiency of cap-dependent translation in the presence of the different gapmer 280 
concentrations. Consistent with previous work (31), these assays showed no gapmer-induced 281 
cellular toxicity (Fig. 6A). Translation inhibition of > 50% was only observed at 500 nM 282 
concentrations of gapmers 1, 2, 5 and 6 (Fig. 6B), which is at least 10-fold higher than the 283 
effective inhibition range for gapmers 1, 2 and 5. Overall, these results suggest that gapmers 284 
targeting the s2m element can inhibit viral replication in the model replicon system in a dose-285 
dependent, sequence-specific manner without causing significant cell toxicity. 286 
SARS-CoV-2 growth is inhibited by LNA gapmers targeting s2m. A high content 287 
screening (HCS) assay was developed to measure the effects of LNA gapmers on infection in 288 
Vero E6 cells infected with SARS-CoV-2. Figure 7A shows a graphical representation of the 289 
HCS assay workflow and an example representative microscopy image, with cells stained for 290 
N protein (488 nm signal). We tested gapmers 1-6, “all” and “scr” at 0.25 µM, 0.5 µM and 291 
1 µM concentrations, alongside a no-gapmer treatment as a negative control, and a 10 µM 292 
remdesivir treatment as a positive control. Our results indicate that gapmers 2 and 5 inhibit 293 
SARS-CoV-2 infection in a dose-dependent manner. At 1 µM concentration, these gapmers 294 
reduced virus replication (measured through N protein expression) to 10.4% and 6.9% of the 295 
no-gapmer control, respectively, with cell viability at 72% and 83%, respectively. 296 
Furthermore, these inhibition levels are comparable to the 10 µM remdesivir control in this 297 
assay (Fig. 7B). Gapmers 1, 3, and 6 have a less profound effect (27%, 31%, and 17% of 298 
non-treated control levels at 1 µM), whereas gapmer 4 shows the highest toxicity levels (54% 299 
viability) besides inhibition to 13% of the non-treated control. In strong agreement with the 300 
astrovirus replicon-based results (Fig. 5D), gapmers 2 and 5 demonstrate the most promising 301 
results in SARS-CoV-2 inhibition assays (Fig. 7B), suggesting these two gapmers could be 302 
preferred for therapeutic development. Consistent with our previous results on other cell lines 303 
(Fig. 6A), the gapmers show no cytotoxic effect on Vero E6 cells in the absence of 304 
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transfection reagent (<5%, Fig. 7C), providing further confidence for potential therapeutic 305 
gymnotic delivery (32). These results are consistent with the results from the astrovirus 306 
replicon system and indicate that gapmers may have sufficient access to their RNA targets to 307 
direct degradation in infected cells and that gapmers against the conserved s2m element or, 308 
by extension, other conserved RNA elements, may act as viable anti-viral agents, warranting 309 
their further exploration as therapeutics. 310 
DISCUSSION 311 
For many RNA viruses, genomic RNA structures play critical roles in the replication 312 
cycle, including in the modulation of the immune response, regulation of virus RNA 313 
replication, virus protein translation, and interactions with host factors. This undoubtedly 314 
impacts on the evolution of both hosts and viruses, leading to selection and conservation of 315 
such structured RNA elements (33). The s2m element, found across different distantly related 316 
RNA viruses (10), represents a good example of this, although its exact role(s) in the virus 317 
life cycle and possible interaction partners are yet to be determined. Nonetheless, the 318 
remarkable conservation of the s2m makes it an attractive target for therapeutic intervention, 319 
which was explored in this study. 320 
We have confirmed that the s2m element in the 3ʹ UTR of SARS-CoV-2 RNA is a feasible 321 
candidate for ASO-based targeting. For this, we designed and successfully tested LNA-based 322 
gapmer ASOs against the s2m. We demonstrated physical gapmer-induced disruption of the 323 
RNA structure, consistent with successful gapmer-target base-pairing interactions, and 324 
RNase H-induced target degradation in vitro. Furthermore, we have demonstrated that the 325 
s2m element can direct gapmer-induced reduction of gene expression in GFP reporter assays 326 
in human cells, likely relying on the demonstrated enzymatic activity of endogenous 327 
RNase H in the nucleus and the cytoplasm (34). 328 
We extended the observation by testing the ability of s2m-targeting gapmers to inhibit 329 
viral replication in an astrovirus-based replicon model system, a rapid functional assay that 330 
does not require access to higher containment level facilities. Astrovirus replicon assays 331 
showed that gapmers against s2m inhibit replication in a sequence-specific, dose-dependent 332 
manner, down to sub-nanomolar range. These observations confirm that gapmers have 333 
significant potential as RNA replication inhibitors. Results from SARS-CoV-2 infection 334 
assays in cell culture are also highly encouraging, with inhibition observed at the 0.25-1 µM 335 
gapmer concentration range. Two of the tested gapmers, 2 and 5, provided consistent 336 
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inhibition results in both systems without increased cellular toxicity. These gapmer results 337 
also highlight specific target regions within the s2m element that could be particularly 338 
promising for the development of therapeutic ASOs. In the cellular environment in the 339 
replicon assays and in bona fide SARS-CoV-2 infection, the differences in gapmer 340 
efficiencies could be attributed to a combination of multiple possible factors, including target 341 
sequence accessibility, nuanced differences in the target structure, other multimolecular 342 
interactions and possible off-target effects. 343 
LNA gapmer-based therapies represent an emerging strategy to specifically target RNAs 344 
for RNase H mediated degradation, proven to be a robust pharmacological mechanism in 345 
both the cytoplasm and the nucleus (34). More broadly, ASO-based therapies have 346 
successfully been applied against myopathies, various genetic disorders, cancers, and virus 347 
infections including cytomegalovirus and Ebola virus (35). With several drug candidates 348 
already approved and many in clinical trials, ASO-based therapies represent a promising 349 
direction thanks to their high specificity, long-term stability, low toxicity, and the relatively 350 
low production cost (36). 351 
There are several reports on using ASOs as potential therapeutics against SARS-CoV-2. 352 
Of particular interest, a recent study by Sun et al. describes in vivo click SHAPE-based 353 
detection of functional structured SARS-CoV-2 RNA elements, which are validated by 354 
targeting with siRNAs and ASOs (37). This study highlights the importance of the conserved 355 
RNA elements across the coronavirus genome and includes in-depth analyses of conserved 356 
RNA elements SL1-4 in the 5ʹ UTR and SL(ORF10), confirming their potential as antiviral 357 
targets. The s2m element has been identified as a discrete structural unit in many studies (6, 358 
15, 23, 37), so is likely to interact with gapmers similarly in different contexts (reporter, 359 
replicon, virus infection). Targeting UTRs represents a rational way to target both genomic 360 
and subgenomic coronavirus RNAs present in the infected cell, hopefully boosting the impact 361 
of the therapeutic agent. Further confidence in UTRs as promising therapeutic targets comes 362 
from our SARS-CoV-2 gapmer inhibition assay (Fig. 6B), where inhibition is observed for 363 
gapmers targeting s2m, but not for the gapmer “all” that targets a conserved nonstructural 364 
ORF1a region (1359-1374 nt), which is only present in the less abundant genomic RNA. 365 
It is worth noting that coronaviruses produce double membrane vesicles inside infected 366 
host cells that are thought to conceal the viral double-stranded RNA replicative intermediate 367 
from cellular defences (38, 39). These vesicles have been proposed to be formed through 368 
virus-induced manipulations of the membrane of the endoplasmic reticulum (40). This 369 
compartmentalization of the SARS-CoV-2 genome in membranous bodies within the host 370 
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cell cytoplasm (24) may reduce access of the ASOs to the s2m element or other viral 371 
genomic targets (although viral mRNAs, which all contain s2m, should still be accessible). In 372 
this regard, it is useful to consider that LNA ASOs have been conjugated with tocopherol and 373 
cholesterol for membrane association in the past (41, 42), which could increase the ability of 374 
ASOs to find their targets. Improved membrane association may also boost gapmer entry into 375 
target cells. The primary targets for SARS-CoV-2 infection are the ACE2 receptor expressing 376 
airway cells, with virus infection gradually decreasing from the proximal to distal respiratory 377 
tract (43).  These cells might be amenable to ASO delivery through aerosol (44), enabling 378 
highly targeted therapeutic administration.  379 
When considering s2m as a target for virus inhibition, it is also worth noting that while it 380 
is a remarkably stable genomic element, conserved across multiple groups of single-stranded 381 
(+) sense RNA viruses, some mutations can arise over time. In the SARS-CoV-2 sequences 382 
from Covid-19 patient samples, some s2m polymorphisms and deletions that are predicted to 383 
destabilise or disrupt the structure have been detected (11, 12). Using a combination of 384 
several gapmers together offers a potential therapeutic strategy to guard against emerging 385 
resistance. 386 
The results described here represent a promising start for further research into targeting 387 
conserved elements in (+)ssRNA viruses, and support development of gapmers and related 388 
ASOs against the s2m element in particular. In the case of SARS-CoV-2, our gapmer designs 389 
offer a strong starting point for further therapeutic development, which may include large 390 
scale optimisation and screening to maximise efficacy in cell culture and animal models, as 391 
well as chemical modifications for optimal delivery to target cells. 392 
MATERIALS AND METHODS 393 
RNA preparation. 3ʹ UTRs and the s2m 47-mer were prepared by in vitro transcription 394 
(IVT). Templates for IVT were generated either by PCR, using Phire Hotstart II polymerase 395 
(Thermo Fisher) according to manufacturer’s instructions, or by hybridising complementary 396 
DNA oligonucleotides (Sigma). Sequences for the PCR primers and the DNA 397 
oligonucleotides are given in Table 2. RNA generated by IVT was purified: IVT products 398 
were separated on polyacrylamide denaturing gel (National Diagnostics), relevant bands were 399 
excised using UV shadowing and electroeluted in TBE (Whatman Elutrap), then cleaned up 400 
using PureLinkTM RNA Microscale Kit (Invitrogen). RNA concentrations were estimated 401 
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using UV absorbance (A260nm) and a calculated extinction coefficient. All RNA sequences 402 
used in this study are provided in Table 1. 403 
Gel-based RNA cleavage assay. Each gapmer was pre-incubated with target RNA in 1× 404 
RNase H buffer (Thermo Scientific) for 10 min at 37 C. 2.5 U of RNase H (Thermo 405 
Scientific) was then added and the reaction incubated for 20 min at 37 C. Reactions were 406 
quenched by adding an equal volume of proteinase K mix (0.5 mg/mL enzyme, 407 
100 mM Tris-HCl pH 7.5, 150 mM NaCl, 12.5 mM EDTA, 1% w/v SDS) and incubating at 408 
50 C for 20 min. RNA was visualised on polyacrylamide 7.5 M urea gel (National 409 
Diagnostics) in TBE using SybrGold (Invitrogen). 410 
Chemical probing of the 3ʹ UTR. To probe RNA structure without gapmers, 5 pmol 411 
RNA (~350 ng) was dissolved in 9 l nuclease-free water, and denatured at 95 C for 90 s, 412 
then cooled on ice for 2 min. RNA was refolded by adding 10 l of 2× SHAPE probing 413 
buffer (80 mM HEPES, pH 7.5, 200 mM KCl, 1 mM MgCl2) and incubating at 37 C for 414 
15 min. 2-methylnicotinic acid imidazolide (NAI) was added to a final concentration of 415 
100 mM in 20 l reaction; in control reactions, same volume of DMSO was added instead. 416 
Reactions were allowed to proceed at 37 C for 5 min and then quenched by adding 10 l of 417 
2 M DTT. RNA was purified by loading quenched samples onto Micro Bio-spin Columns 418 
with Bio-Gel P-6 (BioRad), followed by ethanol precipitation. Purified RNA was then 419 
dissolved in 6 μl water, reverse-transcribed into cDNA and analysed by PAGE as described 420 
below. 421 
To probe RNA structure with gapmers, different amounts of gapmers were added to 422 
refolded RNA, at molar ratios of 0.5×, 1× or 2×, and incubated at 37 °C for 10 min. The same 423 
volume of water was added for the no-gapmer control. After co-incubation, RNA was probed 424 
using NAI as described above. In addition, un-probed input RNA was also subjected to 425 
Sanger sequencing: RNA was dissolved in 5 μl water and supplemented with 1 μl of 10 mM 426 
corresponding ddNTP (Roche), then reverse-transcribed into cDNA and analysed by PAGE 427 
as described below. 428 
Reverse transcription and PAGE analysis of cDNA. 6 μl of each RNA-containing 429 
sample was mixed with 1 μl of 5 μM Cy5-modified RT primer (sequence given in Table 6) 430 
and 0.5 μl of 10 mM dNTPs. The mixture was incubated at 95 °C for 3 min to denature the 431 
RNA and then cooled to 50 °C. RT reaction was started by adding 2 μl of 5× RT buffer 432 
(100 mM Tris pH 8.3, 500 mM LiCl, 15 mM MgCl2, 5 mM DTT) and 0.5 μl Superscript III 433 
enzyme (Invitrogen), mixing quickly with a pipette tip. Reaction was allowed to proceed at 434 
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50 °C for 20 min, then quenched by incubation at 85 °C for 10 min, which inactivates the 435 
enzyme. In order to degrade RNA and liberate the complementary cDNA, the reaction mix 436 
was then supplemented with 0.5 μl of 2 M NaOH and incubated at 95 °C for 10 min. The 437 
reaction was stopped by adding an equal volume of 2× stopping buffer (95% formaldehyde, 438 
20 mM EDTA pH 8.0, 20 mM Tris-HCl pH 7.5, orange G dye) and incubating at 95 °C for 439 
5 min. The resulting cDNA sample was cooled down to 65 °C and analysed on an 8% 440 
Acrylamide:Bis-Acrylamide-Urea gel by electrophoresis. The gel was imaged using Typhoon 441 
FLA 9000 Gel Imager (GE Healthcare). 442 
Quantitative gel analysis and SHAPE reactivity calculation. Signal intensity of each 443 
band on the PAGE gel was detected using ImageQuant TL software and normalized to the 444 
total signal of the whole lane. Raw reactivity was generated by subtracting the signal of NAI 445 
channel from that of the DMSO control channel; reactivities with negative values were 446 
corrected to 0. SHAPE reactivity was generated following the 2/8 % normalization method 447 
(45). To calculate the differences in SHAPE signal in the presence and absence of gapmers, 448 
the lanes of NAI channels with 2× gapmer (+gapmer) or without gapmer (-gapmer) were 449 
used. The signal intensity of each band was normalized to the total signal of the whole lane. 450 
Differences were calculated by subtracting the signal of the +gapmer channel from that of the 451 
-gapmer channel and then rescaled to the signal of the -gapmer channel. 452 
Cryo electron microscopy. 5 µM purified 3ʹ UTR in 10 mM Tris pH 7.6, 10 mM KCl, 453 
10 mM NaCl was annealed by sequential incubation at 95 °C for 2 min, at 50 °C for 2 min, at 454 
37 °C for 5 min and then at room temperature. The sample was supplemented with 455 
1 mM MgCl2. 3 µl of the resultant mixture was applied to glow-discharged (EasiGlow Pelco) 456 
R2/2 Quantifoil grids (Quantifoil). Excess sample was blotted away with a FEI Vitrobot (IV) 457 
(100% humidity, 4 °C, blotting force 0, 3 s blot time) and the grids were vitrified in liquid 458 
ethane. The grids were screened with a 200 kV FEI Talos Arctica microscope with a Falcon 459 
III camera and a data set was collected on a 300 kV FEI Titan Krios microscope equipped 460 
with a Gatan K3 camera. Motion correction, ctf estimation and particle-picking were 461 
performed in Warp (46) and 2D/3D alignments and averaging were carried out with 462 
cryoSPARC 2.15 (47). 463 
Gapmer reporter assays. The s2m sequence or control scrambled sequence of s2m 464 
(s2m_scr) was inserted into the 3ʹ UTR of GFP in H6P plasmid using In-Fusion Cloning kit 465 
(TaKaRa) and verified by sequencing. HEK293ET, HeLa and A459 cells, as well as all stable 466 
cell lines, were grown in IMDM medium supplemented with 10% FCS at 37 °C in 5% CO2. 467 
All cell lines tested negative for mycoplasma. Constructs in H6P plasmids were used to 468 
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produce recombinant lentivirus in HEK293ET cells for the stable expression of GFP reporter 469 
in mammalian cells from a constitutive SFFV promoter. HeLa and A549 stable cell lines 470 
were generated by lentiviral transduction with low MOI (>0.3) to ensure single genomic 471 
integrations and were selected for by drug resistance. 472 
To examine the effect of gapmers on GFP expression, HeLa or A549 cells with a stably 473 
integrated GFP-s2m/s2m_scr reporter were seeded at 5×10
4
 cells per well in 24-well plates. 474 
The following day, cells were transfected with gapmer to achieve 20 nM final concentration 475 
using Lipofectamine RNAiMAX (Thermo Fisher Scientific). Flow cytometry analysis was 476 
performed 72 h after transfection. Cells were washed twice with warm PBS, detached with 477 
trypsin and resuspended in IMDM. All samples were analysed on a BD LSR ii flow 478 
cytometer, using the high throughput system (HTS), and at least 20,000 events were acquired 479 
for each sample. Data were analysed in FlowJo (v10.7.1). Main cell population was identified 480 
and gated on Forward and Side Scatter using the Auto Gate tool and plotted as a histogram to 481 
visualise GFP intensity of cells (measured using B-525 detector). 482 
Virus replicon assays. HEK293T cells (ATCC) were maintained at 37 °C in DMEM 483 
supplemented with 10% fetal bovine serum (FBS), 1 mM L-glutamine, and antibiotics. 484 
Huh7.5.1 cells (obtained from Apath, Brooklyn, NY) (48) were maintained in the same media 485 
supplemented with non-essential amino acids. All cells were mycoplasma tested 486 
(MycoAlert
TM
 PLUS Assay, Lonza); Huh7.5.1 cells were also tested by deep sequencing. 487 
The HAstV1 replicon system is based on the HAstV1 infectious clone, where the virus 488 
genome is left intact up to the end of ORFX, then followed by a foot-and-mouth disease 489 
virus 2A sequence and a Renilla luciferase (RLuc) sequence fused in the ORF2 reading 490 
frame, followed by the last 624 nt of the virus genome and a poly-A tail (Fig. 4A, GenBank 491 
accession number MN030571) (29). The s2m mutations were introduced using site-directed 492 
mutagenesis and all constructs were confirmed by sequencing. The resulting plasmids were 493 
linearized with XhoI prior to T7 RNA transcription. 494 
Huh7.5.1 and HEK293T cells were transfected in triplicate with Lipofectamine 2000 495 
reagent (Invitrogen), using the protocol in which suspended cells are added directly to the 496 
RNA complexes in 96-well plates. For each transfection, 100 ng replicon, 10 ng firefly 497 
luciferase-encoding purified T7 RNA (RNA Clean and Concentrator, Zymo research), the 498 
indicated amount of gapmers, and 0.3 µl Lipofectamine 2000 in 20 µl Opti-Mem (Gibco) 499 
supplemented with RNaseOUT (Invitrogen; diluted 1:1,000 in Opti-Mem) were added to 500 
each well containing 5×10
4
 cells in 100 µl DMEM supplemented with 5% FBS, and 501 
incubated at 37 °C for 12 h (Huh7.5.1) or 18 h (HEK293T). Firefly and Renilla luciferase 502 
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activities were determined using the Dual Luciferase Stop & Glo Reporter Assay System 503 
(Promega). Replicon activity was calculated as the ratio of Renilla (subgenomic reporter) to 504 
Firefly (cap-dependent translation, loading control), normalized by the same ratio for the 505 
control replicon, as indicated for each experiment. Three independent experiments, each in 506 
triplicate, were performed to confirm reproducibility of results. 507 
Cytotoxicity assays. The analysis of gapmer cellular cytotoxicity in HEK293T, Huh7.5.1, 508 
and Vero E6 cells was performed using the CyQUANT LDH cytotoxicity assay (Thermo 509 
Scientific). Leaked cytoplasmic enzyme LDH in cell culture supernatants was quantified after 510 
enzymatic conversion, and absorbance was measured at 490 nm in a 96-well plate reader 511 
according to the manufacturer’s instructions. 512 
SARS-CoV-2 production and infection. Vero E6 cells obtained from Oliver Schwarz 513 
(Institute Pasteur, Paris) were maintained in DMEM modified with high glucose, L-514 
glutamine, phenol red and sodium pyruvate (ThermoFisher, #41966-029) supplemented with 515 
10% FCS at 5% CO2. SARS-CoV-2 strain BetaCoV/England/02/2020 (obtained from Public 516 
Health England) was propagated at 37 °C on Vero E6 cells in DMEM supplemented with 517 
10% FCS at 37 °C. The titer was determined by plaque assay as follows: confluent 518 
monolayers of VeroE6 cells were grown on 6-well plates and incubated with 200 μl of a 10-519 
fold serial dilution of virus stock in DMEM supplemented with 10% FCS for 1 h at room 520 
temperature. These cells were then overlaid with 0.5× DMEM supplemented with 1% FCS 521 
and 1.2% Avicel (BMC Biopolymers, Belgium). After 4 days incubation at 37 ℃, cells were 522 
fixed with 4% formaldehyde in PBS followed by staining with 0.1% toluidine blue (Sigma, 523 
#89640). The titer was calculated as plaque forming units (PFU) per ml.  524 
SARS-CoV-2 infection assay. Vero E6 cells (NIBC, UK) were grown in DMEM 525 
(containing 10 % FBS) at 37 °C and 5% CO2 in 96 well imaging plates (Greiner 655090). 526 
Cells were transfected with individual gapmers at 0.25, 0.5 or 1 µM final concentration using 527 
Lipofectamine 2000 (Thermo Fisher), according to manufacturer’s instructions. At 6 h post 528 
transfection, the media was replaced, and the cells were infected or mock infected with 529 
SARS-CoV-2 at a multiplicity of infection 0.5 PFU/cell. At 22 h post-infection, cells were 530 
fixed, permeabilised and stained for SARS-CoV-2 N protein using Alexa488-labelled-531 
CR3009 antibody (49) and for nuclei (DRAQ7, 647 nm wavelength). The plate was imaged 532 
using the high content screening microscope Opera Phenix from Perkin Elmer with a 5× lens. 533 
The Opera Phenix-associated software Harmony was used to delineate the whole well area 534 
and to determine the total intensities of the Alexa488/N protein and DRAQ7/DNA signals per 535 
said whole well area during image acquisition. The background subtracted Alexa488/N 536 
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intensities were normalised to vehicle treated samples. Toxicity was evaluated using the 537 
DRAQ7/DNA signal normalised to mock treated wells and LDH release-based cytotoxicity 538 
assay. 539 
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FIGURE LEGENDS 722 
Figure 1. s2m is a conserved structural element in the SARS-CoV-2 genome. (A) 723 
Sequence alignment of the s2m element in the 3ʹ UTRs of SARS-CoV-2 and SARS-CoV. 724 
Lines indicate base-pairing regions within the element. (B) The crystal structure of the 725 
SARS-CoV s2m element (adapted from (13)). (C) SHAPE chemical probing of the 3ʹ UTR of 726 
SARS-CoV-2. RNA was denatured and refolded in the presence of 100 mM K
+
 and 0.5 mM 727 
Mg
2+
, then incubated with NAI (+NAI channel) or DMSO control (-NAI channel). NAI 728 
modification was detected by reverse transcription stalling and gel-based analysis. 729 
Sequencing lanes were generated by adding ddT (for A), ddG (for C), ddC (for G) and ddA 730 
(for U) when performing reverse transcription. (D) Annotation of SHAPE signal on the s2m 731 
structure. (E) Bar plot showing the reactivities of structural profiling of gel-based analysis in 732 
our study (Fig. 1C) and in SHAPE-MaP experiment in Manfredonia et al. (23). The s2m 733 
structure is highlighted by shading in green. (F) Representative cryoEM image of the SARS-734 
CoV-2 3ʹ UTR (220 nt) at 2.5 µm defocus. The red arrows indicate features that likely 735 
correspond to views along the long axis of duplex regions. The black line in the lower left is a 736 
50 nm scalebar. (G) The 2D class averages and (H) 3D reconstructions were calculated by 737 
CryoSparc 2.15.0. 738 
Figure 2. Antisense oligomers direct RNase H cleavage of the s2m element and a 739 
conserved single stranded region (ss3) in vitro. Upper panel shows the design of the six 740 
gapmers complementary to the s2m, as well as a non-specific control gapmer “scr” used in 741 
this study (Table 3). The LNA is indicated in orange, s2m-specific phosphorothioate-linked 742 
DNA in pink/purple, other phosphorothioate-linked DNA in grey (“scr” and “all”), 743 
phosphodiester-linked DNA in light grey (“some”). RNase H cleavage of the isolated s2m 744 
(A, D), 3ʹ UTR (B, E), the extended 3ʹ UTR (F) and the predicted single-stranded region ss3 745 
(C). Three target:gapmer molar ratios were tested: 1:0.5, 1:1 and 1:2. Incubation of RNA 746 
target with RNase H alone does not lead to cleavage (RNase H, last lane), and is not driven 747 
by control gapmers with scrambled DNA sequence (“scr”). Incubation of RNA target with 748 
gapmer without the addition of RNase H does not lead to degradation either, but does lead to 749 
the appearance of a retarded band that likely corresponds to target:gapmer duplex. 750 
Figure 3. SHAPE probing reveals RNA structure changes induced by LNA gapmers. (A, 751 
C, E, G) SHAPE probing of SARS-CoV-2 3ʹ UTR structure in the presence or absence of the 752 
gapmer indicated. RNA was denatured and refolded in the presence of 100 mM K
+
 and 753 




, then incubated with different gapmer:target molar ratios (0, 0.5, 1 and 2) and 754 
probed using NAI. (B, D, F, H) Quantification of A, C, E and G, respectively. Analysis of the 755 
differences in SHAPE signal from SARS-CoV-2 3ʹ UTR alone and in the presence of 756 
2× molar excess of the gapmer. Red arrows indicate the start and end points of gapmer target 757 
regions. (A and B) The presence of gapmer 1 induced an increase in SHAPE signal at 758 
positions 70-74 and 79-94, highlighted in orange, indicating that these nucleotides are more 759 
unstructured. A strong decrease in SHAPE signal was observed at positions 60-69, 760 
highlighted in blue, indicating decreased accessibility of these bases, which could be caused 761 
by their base-pairing with the gapmer. (C and D) The reactivity profile in D is similar to that 762 
in B, due to the similar target regions of gapmer 1 and gapmer 2. (E and F) In the presence of 763 
gapmer 3, nucleotides at positions 69-75 are more structured, while nucleotides at positions 764 
76-94 are less structured, as indicated. (G and H) No significant differences in SHAPE signal 765 
could be detected in the presence or absence of the non-specific control gapmer “all”, 766 
indicating that it is unable to cause structural changes in the SARS-CoV-2 3ʹ UTR. 767 
Figure 4. Gapmer-induced reduction of protein levels in cell reporter assays. (A) 768 
Schematic of the GFP reporter assay. (B) Gating and data visualisation strategy of the 769 
reporter assay data. Main cell population was identified and gated on Forward and Side 770 
Scatter using the Auto Gate tool and plotted as a histogram to visualise GFP intensity of cells. 771 
(C) HeLa and A549 cell lines containing a genomic insertion of a GFP reporter construct 772 
without additional insertion in its 3ʹ UTR (GFP), with the s2m sequence in its 3ʹ UTR (GFP-773 
s2m) or with a scrambled sequence insertion in its 3ʹ UTR (GFP-s2m-scr) were analysed by 774 
flow cytometry. Data are representative of two independent experiments. (D-G) Flow 775 
cytometry analysis of the GFP expressing cells. HeLa (D) and A549 (F) cell lines containing 776 
a genomic insertion of a GFP reporter construct with the s2m sequence in its 3ʹ UTR (GFP-777 
s2m) were transfected with 20 nM of the indicated gapmers and analysed 72 h post-778 
transfection by flow cytometry. Treatment with gapmers against the s2m element, but not a 779 
nonspecific control gapmer, induced reduction in fluorescence. HeLa (E) and A549 (G) cell 780 
lines containing a control genomic insertion of a GFP reporter construct with a scrambled 781 
sequence inserted in its 3ʹ UTR (GFP-s2m-scr) were transfected with 20 nM of the indicated 782 
gapmers and analysed 72 h post-transfection by flow cytometry. The control cell lines 783 
containing GFP reporter with a scrambled sequence insertion in the 3ʹ UTR show no 784 
appreciable change in fluorescence upon treatment with the gapmers targeted against the s2m 785 
element. Data are representative of three independent experiments (D-G). 786 
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Figure 5. Inhibition of astrovirus replicon activity by gapmers targeting the SARS-CoV-787 
2 s2m RNA element. (A) Schematic of the SARS-CoV-2 and human astrovirus 1 (HAstV1) 788 
genome organisation. The lower panel represents the astrovirus replicon (pO2RL). FS, 789 
frameshift signal; SG, subgenomic; RLuc, Renilla luciferase; RdRp, RNA dependent RNA 790 
polymerase. The presented virus and replicon genomes are not to scale. (B) Conservation of 791 
the s2m 3ʹ UTR element (two-dimensional representation) between HAstV1, SARS-CoV and 792 
SARS-CoV-2. In the astrovirus replicon, the HAstV1 s2m was switched for the SARS-CoV 793 
or SARS-CoV-2 s2m; the wild-type and chimeric replicons are indicated below. Gapmers 794 
(1, 2, 3 and 4, 5, 6) are colour-coded in light, medium and dark magenta, respectively. (C) 795 
Luciferase activity of the wildtype, chimeric, and replication-deficient (RdRp GDD motif 796 
mutated to GNN) astrovirus replicons measured in Huh7.5.1 (dark blue bars) and HEK293T 797 
(light blue bars) cells. (D) Inhibition of the astrovirus chimeric replicon containing the 798 
SARS-CoV-2 s2m by gapmers at 0.5-500 nM concentration range. (E) Inhibition of the 799 
astrovirus chimeric replicon containing SARS-CoV s2m by gapmers at 0.5-500 nM 800 
concentration range. For D-E, all data are presented as mean ± s.d.; n = 3 biologically 801 
independent experiments, full data and statistical analyses are provided in Tables 4 and 5. 802 
Replicon activity is presented as the ratio of Renilla (subgenomic reporter) to Firefly (cap-803 
dependent translation, loading control), normalized by the same ratio for the untreated control 804 
replicon. 805 
Figure 6. Testing the cytotoxic and off-target effects of gapmers. (A) Toxicity assay for 806 
gapmer-treated cells. Cells were treated with 0.5-500 nM gapmers for 24 h. Supernatant was 807 
used to measure cell viability, calculated as the ratio of released to total lactate 808 
dehydrogenase (LDH) activity; “max” = maximum LDH measured for fully lysed cells. (B) 809 
The effect on translation measured as a readout of capped T7 RNA encoding firefly 810 
luciferase at 0.5-500 nM gapmer concentration, normalized to untreated cells. All data are 811 
presented as mean ± s.d.; n = 3 biologically independent experiments. 812 
Figure 7. Inhibition of SARS-CoV-2 growth by gapmers targeting the s2m RNA 813 
element. (A) Graphic representation of the high content screening assay experiment 814 
workflow: transfection of Vero E6 cells with gapmers followed by infection with SARS-815 
CoV-2, fixation of the plate, labelling and screening. A representative image from the 816 
immunofluorescence-based detection of SARS-CoV-2 infection of Vero E6 cells is shown 817 
below. (B) Vero E6 cells were transfected with gapmers 1-6 against the s2m element or 818 
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control gapmers “all” and “scr” at 0.25 µM, 0.5 µM, and 1 µM final concentration and 819 
infected with SARS-CoV-2, fixed, labelled and analysed. Results are presented as mean ± 820 
s.d.; n = 3 biological replicates; signal normalised to a no-gapmer control. Cell viability was 821 
evaluated using the DRAQ7 signal normalised to mock treated wells. P-values are from two-822 
tailed t-tests with separate variances (ns, p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001). 823 
(C) Toxicity assay for gapmer-treated Vero E6 cells in the absence of transfection reagent. 824 
Cells were treated with 0.25 µM, 0.5 µM, and 1 µM gapmers for 24 h. Supernatant was used 825 
to measure cell viability, calculated as the ratio of released to total lactate dehydrogenase 826 
(LDH) activity; “max” = maximum LDH measured for fully lysed cells.  827 
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TABLES 828 
Table 1. Comparison of s2m SHAPE reactivity data with full SARS-CoV-2 RNA 829 






in vivo (23) 
29724 C 0.000264 0.099 
29725 A 0.001084 0 
29726 U 0.016472 0.16 
29727 U 0 0.039 
29728 U 0 0 
29729 U 0 0.037 
29730 C 0 0.116 
29731 A 0.002515 0.152 
29732 C 0.008073 0 
29733 C 0 0.27 
29734 G 0.216838 1.608 
29735 A 0.215142 2.273 
29736 G 0.279061 0.539 
29737 G 0 0.39 
29738 C 0.018078 0.11 
29739 C 0.018301 0.311 
29740 A 0.028428 0.358 
29741 C 0.056297 0.237 
29742 G 0.05398 0.971 
29743 C 0.036963 0.418 
29744 G 0.144668 0.642 
29745 G 0.874421 1.428 
29746 A 0.084514 2.005 
29747 G 0.451746 1.473 
29748 U 1.442612 1.305 
29749 A 1.08788 2.589 
29750 C 0.318457 1.423 
29751 G 0.72784 0.713 
29752 A 1.64896 3.033 
29753 U 0.065939 2.408 
29754 C 0.193073 0.286 
29755 G 0.243543 0.11 
29756 A 0.412054 0.475 
29757 G 0.582749 0.734 
29758 U 0.01733 0.526 
29759 G 0.021711 0.059 
29760 U 0.132202 0.396 
29761 A 0.17963 0.874 
29762 C 0.102882 0.157 
29763 A 0.322471 0.223 
29764 G 0.107769 0.107 
29765 U 0.104244 0.124 
29766 G 0.121398 0.037 
29767 A 0.255364 0.063 
29768 A 0.349472 0.043 
29769 C 0.577487 0.85 
29770 A 0.137057 1.647 
29771 A 0.283001 0.47 
29772 U 0.510771 0.038 
29773 G 0.068428 0.268 
29774 C 0.336458 0.87 
29775 U 1.229296 3.447 
29776 A 2.914031 4.946 
29777 G 0.192584 0.496 
29778 G 0.1186 0.355 
29779 G 0.637951 0.236 
  831 
Page 28 of 32 
 
Table 2. Gapmers used in this study. 832 
Notation: * = phosphorothioate backbone linkage; [+X] = LNA base X. 833 
Melting temperature predictions were obtained using an online oligo design tool 834 
(https://www.qiagen.com/). 835 
 836 




Gapmer 1 [+A]*[+C]*[+T]*[+C]*C*G*C*G*T*G*G*C*[+C]*[+T]*[+C]*[+G] 85 93 
Gapmer 2 [+T]*[+A]*[+C]*[+T]*C*C*G*C*G*T*G*G*[+C]*[+C]*[+T]*[+C] 81 97 
Gapmer 3 [+G]*[+A]*[+T]*[+C]*G*T*A*C*T*C*C*G*[+C]*[+G]*[+T]*[+G] 78 88 
Gapmer 4 [+G]*[+C]*G*T*G*G*C*C*[+T]*[+C]*[+G] 69 76 
Gapmer 5 [+G]*[+A]*T*C*G*T*A*C*T*C*C*G*C*[+G]*[+T]*[+G] 70 76 
Gapmer 6 [+T]*[+T]*[+C]*A*C*T*G*T*A*C*A*C*T*[+C]*[+G]*[+A] 68 79 
scr [+A]*[+C]*C*G*T*G*C*G*G*T*A*T*T*[+C]*[+G]*[+C] 71 75 
all [+C]*[+A]*[+A]*[+T]*A*A*A*T*T*T*T*A*[+A]*[+C]*[+A]*[+A] 53 50 
some [+C]*[+A]*[+A]*[+T]AAATTTTA[+A]*[+C]*[+A]*[+A] 53 50 
  837 
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Table 3. Sequence of the RNA used in this study. 838 
The sequence in bold corresponds to the extended s2m region common for these RNA 839 
substrates. 840 
 841 
























SARS-CoV-2 ss3 (16 nt). A conserved region predicted to be single-stranded in the genome; positions 1359-




  842 
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Table 4. Statistical analysis for the inhibition assay of chimeric astrovirus replicon 843 
containing SARS-CoV-2 s2m. 844 
P-values are from two-tailed t-tests with separate variances, “ref” represents reference data 845 
set for each calculation. 846 
 847 


















pO2RL-S2S 0 1.0000 0.0362 ref n/a    1.0004 0.0704 ref n/a    
 + Gapmer 1 
0.5 0.2900 0.0288 0.00002 0.0031 1 0.5280 0.0842 0.00196 0.0471 1 
5 0.0218 0.0022 0.00044 0.0094 2 0.0160 0.0022 0.00169 0.0006 2 
50 0.0121 0.0027 0.00042 0.0060 3 0.0013 0.0001 0.00165 0.0003 3 
500 0.0023 0.0006 0.00044 0.0011 4 0.0014 0.0001 0.00165 0.0019 4 
 + Gapmer 2 
0.5 0.2273 0.0216 0.00004 0.0033 1 0.7145 0.0205 0.01400 0.2231 1 
5 0.0367 0.0044 0.00040 0.0098 2 0.0426 0.0002 0.00180 0.0008 2 
50 0.0197 0.0016 0.00044 0.0065 3 0.0051 0.0006 0.00166 0.0003 3 
500 0.0032 0.0001 0.00044 0.0014 4 0.0020 0.0003 0.00165 0.0019 4 
 + Gapmer 3 
0.5 0.5767 0.0618 0.00144 0.0061 1 0.5235 0.0197 0.00451 0.0002 1 
5 0.1591 0.0077 0.00037 0.0147 2 0.3597 0.0210 0.00215 0.0004 2 
50 0.0564 0.0034 0.00044 0.0085 3 0.0184 0.0012 0.00171 0.0002 3 
500 0.0291 0.0018 0.00045 0.0011 4 0.0060 0.0003 0.00167 0.0020 4 
 + Gapmer all 
0.5 0.9289 0.0864 0.28993 ref 1   0.7358 0.0144 0.01937 ref 1   
5 0.6728 0.1103 0.02648 ref 2   0.5923 0.0263 0.00482 ref 2   
50 0.2759 0.0363 0.00002 ref 3   0.3624 0.0101 0.00347 ref 3   
500 0.0678 0.0041 0.00043 ref 4   0.1747 0.0132 0.00181 ref 4   
 + Gapmer 4 
0.5 0.4892 0.0744 0.00204 0.0009 5 0.4808 0.0074 0.00564 0.0072 5 
5 0.1472 0.0064 0.00043 0.0006 6 0.1241 0.0110 0.00174 0.0012 6 
50 0.0467 0.0050 0.00038 0.0048 7 0.0087 0.0003 0.00168 0.0001 7 
500 0.0538 0.0058 0.00036 0.0010 8 0.0114 0.0009 0.00168 0.0004 8 
 + Gapmer 5 
0.5 0.2477 0.0226 0.00003 0.0000 5 0.2607 0.0301 0.00083 0.0001 5 
5 0.0083 0.0015 0.00043 0.0006 6 0.0134 0.0014 0.00169 0.0014 6 
50 0.0006 0.0000 0.00044 0.0043 7 0.0011 0.0000 0.00165 0.0001 7 
500 0.0008 0.0001 0.00044 0.0012 8 0.0012 0.0001 0.00165 0.0004 8 
 + Gapmer 6 
0.5 0.9037 0.1248 0.31172 0.0542 5 0.9549 0.0280 0.38466 0.0002 5 
5 0.6675 0.0378 0.00039 0.0005 6 0.5919 0.0771 0.00255 0.0815 6 
50 0.4311 0.0738 0.00144 0.0078 7 0.3026 0.0254 0.00133 0.0003 7 
500 0.0502 0.0045 0.00040 0.0011 8 0.3622 0.0107 0.00341 0.0003 8 
 + Gapmer scr 
0.5 1.1758 0.0355 0.00388 ref 5   0.6406 0.0284 0.00604 ref 5   
5 0.9914 0.0404 0.79653 ref 6   0.7211 0.0454 0.00716 ref 6   
50 0.7626 0.0868 0.02795 ref 7   0.7276 0.0105 0.01966 ref 7   
500 0.5190 0.0305 0.00007 ref 8   0.9490 0.0322 0.33904 ref 8   
pO2RL-GNN 0 0.0014 0.0001 0.00044 n/a    0.0039 0.0002 0.00166 n/a    
  848 
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Table 5. Statistical analysis for the inhibition assay of chimeric astrovirus replicon 849 
containing SARS-CoV s2m. 850 
P-values are from two-tailed t-tests with separate variances, “ref” represents reference data 851 
set for each calculation. 852 
 853 


















pO2RL-S1S 0 1.0000 0.0545 ref n/a    1.0000 0.0623 ref n/a    
 + Gapmer 1 
0.5 0.8509 0.0604 0.03426 0.6572 1 1.0472 0.0453 0.35359 0.0074 1 
5 0.1771 0.0263 0.00022 0.0038 2 0.3910 0.0099 0.00287 0.0015 2 
50 0.0241 0.0002 0.00104 0.0010 3 0.0683 0.0041 0.00143 0.0012 3 
500 0.0024 0.0005 0.00099 0.0012 4 0.0019 0.0002 0.00130 0.0004 4 
 + Gapmer 2 
0.5 0.6292 0.0334 0.00135 0.0067 1 1.0877 0.0541 0.14094 0.0064 1 
5 0.0985 0.0243 0.00022 0.0031 2 0.3316 0.0248 0.00091 0.0002 2 
50 0.0211 0.0014 0.00103 0.0010 3 0.0838 0.0032 0.00150 0.0013 3 
500 0.0018 0.0004 0.00099 0.0012 4 0.0035 0.0003 0.00130 0.0004 4 
 + Gapmer 3 
0.5 0.6064 0.0964 0.00738 0.0217 1 0.8500 0.0385 0.03223 0.5561 1 
5 0.5098 0.0595 0.00048 0.0131 2 0.7614 0.0152 0.01747 0.0100 2 
50 0.3686 0.0543 0.00014 0.0031 3 0.3413 0.0187 0.00149 0.0010 3 
500 0.1088 0.0090 0.00096 0.0005 4 0.2475 0.0171 0.00123 0.0000 4 
 + Gapmer all 
0.5 0.8741 0.0582 0.05250 ref 1   0.8704 0.0396 0.04772 ref 1   
5 0.7915 0.0870 0.03247 ref 2   0.9786 0.0476 0.66236 ref 2   
50 0.6496 0.0348 0.00152 ref 3   0.8390 0.0480 0.02656 ref 3   
500 0.2983 0.0176 0.00084 ref 4   0.5776 0.0198 0.00398 ref 4   
 + Gapmer 4 
0.5 0.6876 0.0649 0.00342 0.0111 5 0.7841 0.0373 0.01146 0.8771 5 
5 0.5680 0.0599 0.00079 0.0062 6 0.5916 0.0205 0.00414 0.0006 6 
50 0.1602 0.0190 0.00047 0.0003 7 0.2470 0.0174 0.00120 0.0016 7 
500 0.0527 0.0040 0.00104 0.0064 8 0.0503 0.0060 0.00131 0.0029 8 
 + Gapmer 5 
0.5 0.6684 0.0822 0.00664 0.0141 5 0.8532 0.0103 0.05175 0.0614 5 
5 0.4641 0.0680 0.00056 0.0050 6 0.5175 0.0132 0.00410 0.0006 6 
50 0.0988 0.0074 0.00102 0.0009 7 0.4381 0.0464 0.00037 0.0009 7 
500 0.0130 0.0015 0.00101 0.0055 8 0.0449 0.0019 0.00140 0.0030 8 
 + Gapmer 6 
0.5 0.6259 0.0688 0.00218 0.0055 5 0.6856 0.0061 0.01223 0.0428 5 
5 0.7125 0.0769 0.00817 0.0425 6 0.8100 0.0509 0.01622 0.8267 6 
50 0.7758 0.0681 0.01249 0.2694 7 0.7181 0.0469 0.00424 0.0490 7 
500 0.1180 0.0141 0.00068 0.0068 8 0.5621 0.0169 0.00426 0.0477 8 
 + Gapmer scr 
0.5 0.9305 0.0682 0.24332 ref 5   0.7792 0.0361 0.01099 ref 5   
5 0.9049 0.0189 0.08136 ref 6   0.8021 0.0271 0.01881 ref 6   
50 0.8373 0.0435 0.01717 ref 7   0.8405 0.0579 0.03174 ref 7   
500 0.5072 0.0642 0.00061 ref 8   0.7127 0.0642 0.00514 ref 8   
pO2RL-GNN 0 0.0012 0.0001 0.00099 n/a    0.0032 0.0004 0.00130 n/a    
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S2M_R IVT primer AATTCACTGTACACTCGATCGTACTCCGCGTGGCCTCG
GTGAACTCCTATAGTGAGTCGTATTAAAAAAC 
COV19_RT SHAPE Primer Cy5-CTCTTCCATATAGGCAGCTC 
 857 







